Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150693 | 0.86 | HTT (0.69) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL6806837 | 0.78 | ALDH1A1 (0.66) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL23109708 | 0.78 | LMNA (0.82) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL27180963 | 0.77 | SMN1; SMN2 (0.70) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL30926988 | 0.77 | SMN1; SMN2 (0.70) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL7144948 | 0.77 | ALDH1A1 (0.67) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL8628044 | 0.77 | SMN1; SMN2 (0.62) | KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7153167 | 0.76 | ALDH1A1 (0.67) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL7150208 | 0.76 | KMT2A (0.70) | KMT2AMEN1HTTALDH1A1KDM4E | |
| SCHEMBL7144933 | 0.76 | ALDH1A1 (0.66) | KMT2AMEN1HTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504676-B2 | Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-11-29 | — | — | US | disclosed |
| US-20140179679-A1 | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20110112098-A1 | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112098-A1 | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179679-A1 | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES | SYK, BTK, TYRO3 | KMT2A 1901/4885MEN1 4288/4885HTT 4431/4885 |
| US-20110112098-A1 | MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES | SYK, BTK, TYRO3 | KMT2A 1901/4885MEN1 4288/4885HTT 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.